{"id":"jnj-79635322","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-17A is a key driver of inflammation in autoimmune and inflammatory conditions. By binding to and neutralizing IL-17A, JNJ-79635322 reduces the inflammatory cascade and immune cell activation. This mechanism is particularly relevant for conditions characterized by Th17 cell-mediated inflammation, such as psoriasis and other immune-mediated inflammatory diseases.","oneSentence":"JNJ-79635322 is a monoclonal antibody that targets and inhibits IL-17A, a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:41.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT07258511","phase":"PHASE3","title":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-02-04","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT06768489","phase":"PHASE1","title":"A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-04","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT05652335","phase":"PHASE1","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-22","conditions":"Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis","enrollment":180},{"nctId":"NCT07266441","phase":"PHASE2","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-02-08","conditions":"Multiple Myeloma","enrollment":157},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JNJ-79635322","genericName":"JNJ-79635322","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JNJ-79635322 is a monoclonal antibody that targets and inhibits IL-17A, a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases. Used for Psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}